Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

Stopped early · Phase 1

Conditions studied: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer

In brief

This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.

Key facts

Study ID

NCT07408089

Run by

Boundless Bio, Inc.

People needed

8

Starts

2026-02-25

Expected to finish

2026-07-28

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• The START Center for Cancer Research — Los Angeles, California, United States
• The START Center for Cancer Research — Lake Success, New York, United States
• NEXT Oncology — Austin, Texas, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States
• NEXT Oncology — Houston, Texas, United States
• NEXT Oncology — San Antonio, Texas, United States
• The START Center for Cancer Care — San Antonio, Texas, United States
• NEXT Oncology — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.